The estimated Net Worth of University Partners Ii, L.P... is at least $759 mil dollars as of 27 June 2016. University P owns over 350,000 units of Selecta Biosciences Inc stock worth over $759,038 and over the last 8 years University sold SELB stock worth over $0.
University has made over 2 trades of the Selecta Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently University bought 350,000 units of SELB stock worth $4,900,000 on 27 June 2016.
The largest trade University's ever made was buying 350,000 units of Selecta Biosciences Inc stock on 27 June 2016 worth over $4,900,000. On average, University trades about 350,000 units every 0 days since 2016. As of 27 June 2016 University still owns at least 862,543 units of Selecta Biosciences Inc stock.
You can see the complete history of University P stock trades at the bottom of the page.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit..., eCarl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: